Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI)

References

• Mislang AR, Wildes TM, Kanesvaran R, et al. Adherence to oral cancer therapy in older adults: the International Society of Geriatric Oncology (SIOG) taskforce recommendations. Cancer Treat Rev. 2017;57:58–66.
   PubMed Web of Science ®Google Scholar
• Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin. 2009;59(1):56–66.
   PubMed Web of Science ®Google Scholar
• Adherence to long-term therapies. Evidence for action. World Health Organization. 2003. Available at: https://www.who.int/chp/knowledge/publications/adherence_full_report.pdf. Accessed June 2021.
   Google Scholar
• Cortes JE, Mauro MJ, Goldberg SL, et al. Quality of life during early tyrosine kinase inhibitor treatment as self-reported by chronic myeloid leukemia patients participating in a prospective observational study (SIMPLICITY). Blood. 2011;118(21):4435–4435.
   Google Scholar
• Efficace F, Baccarani M, Rosti G, et al. Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study. Br J Cancer. 2012;107(6):904–909.
   PubMed Web of Science ®Google Scholar
• Le Calloch R, Lacut K, Le Gall-Ianotto C, et al. Non-adherence to treatment with cytoreductive and/or antithrombotic drugs is frequent and associated with an increased risk of complications in patients with polycythemia vera or essential thrombocythemia (Ouest study). Haematologica. 2018;103(4):607–613.
   PubMed Web of Science ®Google Scholar
• Cransac A, Aho S, Chretien M-L, et al. Adherence to immunomodulatory drugs in patients with multiple myeloma. PLoS One. 2019;14(3):e0214446.
   PubMed Web of Science ®Google Scholar
• Morisky DE, Ang A, Krousel-Wood M, et al. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertension. 2008;10(5):348–354.
   PubMed Web of Science ®Google Scholar
• Krousel-Wood M, Islam T, Webber LS, et al. New medication adherence scale versus pharmacy fill rates in seniors with hypertension. Am J Manag Care. 2009;15(1):59–66.
   PubMed Web of Science ®Google Scholar
• Morisky Widget Software ©. Available at: https://morisky.org/. Accessed June 2021.
   Google Scholar
• Ogedegbe G, Schoenthaler A, Richardson T, et al. An RCT of the effect of motivational interviewing on medication adherence in hypertensive African Americans: rationale and design. Contemp Clin Trials. 2007;28(2):169–181.
   PubMed Web of Science ®Google Scholar
• Elm JJ, Kamp C, Tilley BC, NINDS NET-PD Investigators and Coordinators, et al. Self-reported adherence versus pill count in Parkinson's disease: the NET-PD experience. Mov Disord. 2007;22(6):822–827.
   PubMed Web of Science ®Google Scholar
• Afonso NM, Nassif G, Aranha ANF, et al. Low-density lipoprotein cholesterol goal attainment among high-risk patients: does a combined intervention targeting patients and providers work? Am J Manag Care. 2006;12(10):589–594.
   PubMed Web of Science ®Google Scholar
• Berry DL, Blonquist TM, Hong F, et al. Self-reported adherence to oral cancer therapy: relationships with symptom distress, depression, and personal characteristics. Patient Prefer Adherence. 2015;9:1587–1592.
   PubMed Web of Science ®Google Scholar
• Phatak HM, Thomas J. Relationships between beliefs about medications and nonadherence to prescribed chronic medications. Ann Pharmacother. 2006;40(10):1737–1742.
   PubMed Web of Science ®Google Scholar
• Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med. 2000;342(17):1255–1265.
   PubMed Web of Science ®Google Scholar
• Jakavi Summary of Product Characteristics. Novartis Pharmaceuticals UK Ltd. 2020. Available at: https://www.medicines.org.uk/emc/product/4298/smpc#gref. Accessed June 2021.
   Google Scholar
• Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799–807.
   PubMed Web of Science ®Google Scholar
• Harrison C, Kiladjian J-J, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787–798.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Kantarjian HM, Estrov Z, et al. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood. 2012;120(6):1202–1209.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Gotlib J, Mesa RA, et al. Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. J Hematol Oncol. 2017;10(1):156.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363(12):1117–1127.
   PubMed Web of Science ®Google Scholar
• Palandri F, Palumbo GA, Bonifacio M, et al. Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis. Oncotarget. 2017;8(45):79073–79086.
   PubMedGoogle Scholar
• Tefferi A, Litzow MR, Pardanani A. Long-term outcome of treatment with ruxolitinib in myelofibrosis. N Engl J Med. 2011;365(15):1455–1457.
   PubMed Web of Science ®Google Scholar
• Breccia M, Guglielmelli P, Malato A, et al. Real world data on ruxolitinib (RUX) in myelofibrosis (MF): 6 months (MOS) interim analysis of Italian ROMEI study (CINC424AIT04). 47° Congresso Nazionale della Società Italiana di Ematologia (SIE), Rome, Italy, 7–9 October 2019. Abstract 0052.
   Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the world Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405.
   PubMed Web of Science ®Google Scholar
• Park Y-H, Kim H, Jang S-N, et al. Predictors of adherence to medication in older Korean patients with hypertension. Eur J Cardiovasc Nurs. 2013;12(1):17–24.
   PubMed Web of Science ®Google Scholar
• Gadkari AS, McHorney CA. Unintentional non-adherence to chronic prescription medications: how unintentional is it really? BMC Health Serv Res. 2012;12:98.
   PubMed Web of Science ®Google Scholar
• Wroe AL. Intentional and unintentional nonadherence: a study of decision making. J Behav Med. 2002;25(4):355–372.
   PubMed Web of Science ®Google Scholar
• Ley P. Psychological studies of doctor–patient communication. In: Rachman S, editor. Contributions to medical psychology. Vol. 1. Oxford (UK): Pergamon; 1978.
   Google Scholar